文献速递血栓与止血

如何为肥胖患者选择口服抗凝药

How I treat obese patients with oral anticoagulants.
PubMed 文献 · Blood · 2020-01-01

肥胖是全球性健康问题,与静脉血栓栓塞症和房颤相关,二者均需抗凝治疗。肥胖及减重手术可影响抗凝药的吸收、排泄、药代动力学和药效学,导致最佳抗血栓策略不明确,尤其病态肥胖者。本文通过4例病例展示临床挑战并基于现有证据给出建议。

要点

  • 肥胖影响口服抗凝药的药代和药效,病态肥胖者抗凝策略不确定性最大。
  • 减重手术可改变抗凝药吸收和代谢,需个体化评估。
  • 本文基于4例病例和文献综述提出肥胖患者抗凝管理建议。

核心结论

  • 肥胖及减重手术影响抗凝药药代和药效,病态肥胖者最佳抗血栓策略尚不明确,需基于现有证据个体化决策。

研究设计与样本

  • 本文为综述性文章,通过4例肥胖患者抗凝病例讨论临床挑战,并复习文献提出建议。

主要发现

  • 肥胖与静脉血栓栓塞症和房颤相关,二者均需抗凝治疗。
  • 肥胖及减重手术可影响多种抗凝药的吸收、排泄、药代动力学和药效学。
  • 近年多项研究探讨肥胖人群抗凝使用,提供更多见解。

临床怎么用

  • 对肥胖患者,尤其是病态肥胖者,应基于现有最佳证据个体化选择抗凝策略。
  • 需考虑肥胖及减重手术对口服抗凝药药代和药效的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Obesity has become a major threat to health worldwide. The prevalence of obesity is rapidly increasing, so much so that the World Health Organization has declared obesity as a global epidemic. Obesity is associated with multiple health problems, including venous thromboembolism and atrial fibrillation, both of which are treated with anticoagulation. However, obesity and treatments for obesity such as bariatric surgery can influence absorption, excretion, pharmacokinetics, and pharmacodynamics of various anticoagulants. This results in uncertainty regarding the best antithrombotic strategies in this population, particularly in the morbidly obese. In the recent years, several studies have attempted to investigate anticoagulation use in this population and provided more insight. Herein, we present 4 cases of anticoagulant use in the obese to illustrate the common challenges faced by clinicians and discuss our approach. Whenever possible, we provide a review of the literature and base our recommendations on the best available evidence.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Wang TF, Carrier M. How I treat obese patients with oral anticoagulants. Blood. 2020. PMID: 31978224. doi:10.1182/blood.2019003528

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。